SNOWMASS VILLAGE, COLO.—A major workforce shortage, a population of patients taking immunosuppressants where safety concerns and the patient experience are critical, and an increasing focus on remote patient monitoring and telehealth are driving a discussion regarding the role digital wearables play in rheumatologic care. “We need to be more thoughtful and efficient in taking care…
ATLANTA—At the ACR/ARP 2019 Annual Meeting, several widely renowned experts across an array of specialty subjects provided a comprehensive and compelling review of advances in the understanding, diagnosis and treatment of a number of rheumatologic conditions. Sjögren’s Syndrome Frederick Vivino, MD, FACR, chief of rheumatology at Penn Presbyterian Medical Center and professor of clinical medicine…
Living like a king has its price. And while kings and queens are primarily something of yesteryear, the vast majority of those living in reasonably wealthy nations can now live like kings. Now, back to that price. Gout, once known as the disease of kings, has been around at least since the time of the…
ATLANTA—Rheumatic diseases have been the subject of a range of public health campaigns and reports over the past decade, but improving their visibility remains a work in progress, a Centers for Disease Control and Prevention (CDC) expert said at the 2019 ACR/ARP Annual Meeting. A growing attention to pain and the opioid crisis may help…
How does a patient transition from health to active SLE? This question is the crux of the research conducted by Judith A. James, MD, PhD, and colleagues…
NEW YORK (Reuters Health)—Low-dose methotrexate can be associated with gastrointestinal, pulmonary, infectious, hematologic and other adverse effects, according to an analysis of the Cardiovascular Inflammation Reduction Trial (CIRT). “Methotrexate is not a benign drug, even at dosages used for rheumatic diseases,” Daniel H. Solomon, MD, MPH of Brigham and Women’s Hospital, Boston, tells Reuters Health…
Recent research assessed the risk of gout in patients with type 2 diabetes mellitus prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with those prescribed a glucagon-like peptide-1 (GLP-1) agonist. The study found patients on the SGLT2 inhibitor had a lower rate of gout, suggesting SGLT2 inhibitors may actually reduce the risk of gout among this patient population…
Public health agencies have been raising the profile of arthritis…
During a session at the 2019 ACR/ARP Annual Meeting, Lisa Christopher-Stine, MD, MPH, provided valuable recommendations and practical insights into the care and treatment of myositis patients…
ATLANTA—The authors of the new draft ACR treatment guideline for the management of gout presented the draft guideline on Nov. 13 at the 2019 ACR/ARP Annual Meeting. Based on evidence from more than 130 published studies, there are 42 recommendations, of which 16 were strong, including 27 for urate-lowering therapy (ULT) management, 13 of which…